医学
代谢综合征
肥胖
减肥
重症监护医学
脂肪肝
葡萄糖稳态
人口
生活质量(医疗保健)
疾病
糖尿病
外科
内科学
胰岛素抵抗
内分泌学
环境卫生
护理部
作者
Paúl Cordero,Jia’an Li,Jude A. Oben
标识
DOI:10.4997/jrcpe.2017.414
摘要
Obesity is the pandemic of the 21st century. Obesity comorbidities, including hypertension, dyslipidaemia and glucose intolerance define metabolic syndrome, which increases mortality risk and decreases the quality of life. Compared with lifestyles (diet and physical activity) and pharmacological interventions, bariatric surgery is by far the most effective treatment for obesity and its comorbidities. This minimally invasive surgical treatment is based on an increase of satiety (by hormonal regulation and decreasing stomach volume) or a decrease in nutrient retention (gastric and/or intestinal resection). Bariatric surgery has widely demonstrated a beneficial effect on excess body weight loss, cardiovascular risk, dyslipidaemia, non-alcoholic fatty liver disease or glucose homeostasis, among other obesity-related metabolic diseases. This review describes current efforts for the implementation of bariatric surgery in metabolic syndrome, which are mainly focused on the formulation of key definition criteria for targeting the most suitable population for this therapeutic approach. Patients should undergo appropriate nutritional and psychological follow up in order to achieve and maintain weight loss milestones and a healthy metabolic status.
科研通智能强力驱动
Strongly Powered by AbleSci AI